PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Armata Pharmaceuticals Inc. (ARMP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS04216R1023
CUSIP04216R102
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$96.33M
EPS-$1.91
Revenue (TTM)$4.53M
Gross Profit (TTM)-$29.51M
EBITDA (TTM)-$39.92M
Year Range$1.07 - $5.26
Target Price$8.00
Short %0.12%
Short Ratio0.73

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Armata Pharmaceuticals Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Armata Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%NovemberDecember2024FebruaryMarchApril
-100.00%
19.37%
ARMP (Armata Pharmaceuticals Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Armata Pharmaceuticals Inc. had a return of -21.91% year-to-date (YTD) and 57.14% in the last 12 months. Over the past 10 years, Armata Pharmaceuticals Inc. had an annualized return of -52.10%, while the S&P 500 had an annualized return of 10.55%, indicating that Armata Pharmaceuticals Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-21.91%6.30%
1 month-32.35%-3.13%
6 months18.78%19.37%
1 year57.14%22.56%
5 years (annualized)-9.05%11.65%
10 years (annualized)-52.10%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202416.98%3.96%6.09%
2023-13.29%-25.00%-2.67%47.95%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ARMP is 71, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of ARMP is 7171
Armata Pharmaceuticals Inc.(ARMP)
The Sharpe Ratio Rank of ARMP is 6666Sharpe Ratio Rank
The Sortino Ratio Rank of ARMP is 7676Sortino Ratio Rank
The Omega Ratio Rank of ARMP is 7373Omega Ratio Rank
The Calmar Ratio Rank of ARMP is 7272Calmar Ratio Rank
The Martin Ratio Rank of ARMP is 6868Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Armata Pharmaceuticals Inc. (ARMP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ARMP
Sharpe ratio
The chart of Sharpe ratio for ARMP, currently valued at 0.45, compared to the broader market-2.00-1.000.001.002.003.000.45
Sortino ratio
The chart of Sortino ratio for ARMP, currently valued at 1.59, compared to the broader market-4.00-2.000.002.004.006.001.59
Omega ratio
The chart of Omega ratio for ARMP, currently valued at 1.19, compared to the broader market0.501.001.501.19
Calmar ratio
The chart of Calmar ratio for ARMP, currently valued at 0.52, compared to the broader market0.001.002.003.004.005.000.52
Martin ratio
The chart of Martin ratio for ARMP, currently valued at 1.76, compared to the broader market0.0010.0020.0030.001.76
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.92, compared to the broader market-2.00-1.000.001.002.003.001.92
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.006.002.78
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.47, compared to the broader market0.001.002.003.004.005.001.47
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.64, compared to the broader market0.0010.0020.0030.007.64

Sharpe Ratio

The current Armata Pharmaceuticals Inc. Sharpe ratio is 0.45. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00NovemberDecember2024FebruaryMarchApril
0.45
1.92
ARMP (Armata Pharmaceuticals Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Armata Pharmaceuticals Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-100.00%
-3.50%
ARMP (Armata Pharmaceuticals Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Armata Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Armata Pharmaceuticals Inc. was 100.00%, occurring on Dec 28, 2022. The portfolio has not yet recovered.

The current Armata Pharmaceuticals Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Jul 13, 20005652Dec 28, 2022
-87.07%Feb 5, 1996657Sep 10, 1998342Jan 19, 2000999
-58.44%Mar 14, 200025Apr 17, 200052Jun 30, 200077
-45.21%May 23, 1994138Dec 6, 1994271Jan 3, 1996409
-35.33%Jan 20, 20008Jan 31, 20008Feb 10, 200016

Volatility

Volatility Chart

The current Armata Pharmaceuticals Inc. volatility is 28.92%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
28.92%
3.58%
ARMP (Armata Pharmaceuticals Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Armata Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items